Most researchers searching for CJC-1295 in Penna rapidly learn that local retail options are virtually absent. What this means for Penna researchers is that your location matters far less than your ability to evaluate vendor quality — and those evaluation tools are within reach of all serious researchers. Separating quality CJC-1295 from the rest of the market depends on three things: an HPLC chromatogram documenting ≥98% purity, mass spec data verifying the correct molecular weight, and a batch-specific endotoxin panel. The sections below cover what Penna researchers need to know about purchasing, testing, and working with CJC-1295 for scientific research use.
CJC-1295: What the Research Shows
CJC-1295 with DAC (Drug Affinity Complex) is a GHRH analogue with an extended half-life achieved through DAC technology that enables covalent binding to albumin. This modification extends the half-life from minutes (for native GHRH) to approximately 6-8 days, creating a sustained elevation in basal GH levels rather than the pulsatile pattern produced by GHRP compounds. This pharmacokinetic distinction is significant for research design: CJC-1295 based on CJC-1295 with DAC produces a different GH secretion pattern than GHRP compounds, with different downstream effects on IGF-1 and protein synthesis. Researchers in Penna comparing compounds in this class should account for these pharmacokinetic differences in their experimental design.
Buying CJC-1295: Quality Markers to Look For
Evaluating CJC-1295 vendors begins with the COA: locate the batch-specific certificate before purchasing, not after. Endotoxin testing in the COA is essential for any injectable research use — endotoxins from bacterial cell wall components can trigger dangerous inflammatory cascades even at very low concentrations. Strong quality indicators beyond COA quality: multi-year operating history, responsive technical support who understand testing methodology, and cold chain packaging that protects product integrity. Bacteriostatic water is the appropriate reconstitution medium for CJC-1295 — it contains 0.9% benzyl alcohol that prevents microbial contamination and extends reconstituted shelf life to 30 days refrigerated.
Order CJC-1295 — ships to Penna
COA-verified · International tracking · Research grade
As a research compound, CJC-1295 has not been through the clinical trial process required for pharmaceutical approval — its safety profile is characterised by preclinical data and restricted human research data. Proper handling of CJC-1295 requires sterile reconstitution technique — alcohol-swabbed septum, fresh needles, clean working environment — and temperature control throughout the entire workflow. Bacterial endotoxin contamination is the greatest safety hazard associated with research-grade peptides — verify endotoxin testing is documented in your batch COA before any injectable research application. Researchers combining CJC-1295 with other compounds should check the research literature for any reported interactions before proceeding with any multi-compound protocol.
Frequently Asked Questions
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
